GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Earnings Yield (Joel Greenblatt) %
中文

Novo Nordisk A/S (Novo Nordisk A/S) Earnings Yield (Joel Greenblatt) % : 3.38% (As of Dec. 2023)


View and export this data going back to 1981. Start your Free Trial

Novo Nordisk A/S Earnings Yield (Joel Greenblatt) % Definition

Novo Nordisk A/S's Enterprise Value for the quarter that ended in Dec. 2023 was $460,738 Mil. Novo Nordisk A/S's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $15,350 Mil. Novo Nordisk A/S's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was 3.38%.

The historical rank and industry rank for Novo Nordisk A/S's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

NVO' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 2.62   Med: 5.11   Max: 8.5
Current: 2.73

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Novo Nordisk A/S was 8.50%. The lowest was 2.62%. And the median was 5.11%.

NVO's Earnings Yield (Joel Greenblatt) % is ranked better than
86.51% of 1394 companies
in the Biotechnology industry
Industry Median: -15.615 vs NVO: 2.73

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Novo Nordisk A/S's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 17.77%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Novo Nordisk A/S Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Novo Nordisk A/S's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.32 5.35 3.48 3.29 3.38

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.29 3.11 3.28 3.11 3.38

Competitive Comparison

For the Biotechnology subindustry, Novo Nordisk A/S's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S Earnings Yield (Joel Greenblatt) % Distribution

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Earnings Yield (Joel Greenblatt) % falls into.



Novo Nordisk A/S Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Novo Nordisk A/Ss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=15394.159/460738.3965
=3.34 %

Novo Nordisk A/S's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $15,350 Mil.



Novo Nordisk A/S  (NYSE:NVO) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Novo Nordisk A/S Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry
Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.